Avalanche Biotechnologies announced it will not initiate a Phase 2b trial for AVA-101 in the second half of 2015 after further analysis of Phase 2a data. The company plans to conduct additional preclinical studies to determine the optimal dose and delivery method for AVA-101 and AVA-201. Financial results for the second quarter of 2015 showed a revenue of $0.2 million and a loss per share of 38 cents. The company's cash and equivalents were $279.6 million as of June 30, 2015.
documents/vol00010-efta01368503-pdf.pdf
{"title":"Avalanche Biotechnologies Update on AVA-101 Program","key_people":["Jeremy R. Cooke"],"document_date":"2015-08-13","document_type":"media","key_organizations":["Avalanche Biotechnologies"],"reference_numbers":["DB-SDNY-0060257","SDNY_GM_00206441","EFTA01368503"]}